Genolution

Genolution Net Margin

The Net Profit Margin of Genolution (225220.KQ) as of Oct 22, 2026 is -123.80 %. In the previous year, Net Profit Margin was -95.65 % — a change of 29.43% (lower).

Net Margin

-123.80 %

YoY

29.43%

Last updated:

Net Profit Margin of Genolution is 2025 -123.80 % . Net Profit Margin of Genolution was 2024 -95.65 % . It decreases by 29.43% lower compared to the previous year.

Genolution's net margin stands at -123.8%, down from 47.2% several years earlier.

The Genolution Net Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Margin
Date
Net Margin
Jan 1, 2018
41.26 KRW
Jan 1, 2019
-7.26 KRW
Jan 1, 2020
37.57 KRW
Jan 1, 2021
47.22 KRW
Jan 1, 2022
38.34 KRW
Jan 1, 2023
-56.86 KRW
Jan 1, 2024
-95.65 KRW
Jan 1, 2025
-123.80 KRW
The Genolution Net Margin history
YEARNet MarginYoY
-123.80 %+29.43%
-95.65 %+68.22%
-56.86 %-248.30%
38.34 %-18.81%
47.22 %+25.70%
37.57 %-617.14%
-7.26 %-117.61%
41.26 %+74.41%
23.66 %+302.99%
5.87 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Genolution Stock analysis

What does Genolution do? Genolution Inc develops automated nucleic acid extraction devices, nucleic acid extraction reagents, and molecular diagnostic products. The company also offers ribonucleic acid interference services. Its products are distributed domestically and internationally, serving customers in the biotechnology and healthcare sectors. The firm generates revenue through the sale of these products and services to research institutions, laboratories, and healthcare providers. The company's core offerings include nucleic acid extractors, reagents, and diagnostic products, which are used in molecular biology and medical diagnostics. Genolution Inc targets biotech firms, hospitals, and research facilities as key buyers of its technology. Its domestic market presence complements its international distribution channels. Genolution Inc's business model relies on selling its automated extraction devices and reagents to customers requiring efficient nucleic acid processing solutions. The company's molecular diagnostic products cater to healthcare applications, while its ribonucleic acid interference services support advanced research needs. Revenue streams are derived from both product sales and service contracts within the biotechnology industry. Genolution is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Genolution stock

Net Profit Margin of Genolution is -123.80 % in 2025.

Net Profit Margin of Genolution changed from -95.65 % to -123.80 %, representing a 29.43% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Profit Margin Genolution since 2006 – with annual values, charts, and detailed analysis.

Net Margin measures the percentage of revenue that becomes net profit after all expenses. It is the ultimate measure of a company's profitability.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Profit Margin's Genolution with sector peers and the industry average to assess whether it is attractive.

To evaluate Net Profit Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Net Profit Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Genolution

All Key Metrics — Genolution